Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for OptimizeRx (OPRX) over the last 17 years, with Q3 2025 value amounting to $2.9 million.

  • OptimizeRx's Net Cash Flow rose 15141.39% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year decrease of 4530.95%. This contributed to the annual value of -$472000.0 for FY2024, which is 8916.69% up from last year.
  • As of Q3 2025, OptimizeRx's Net Cash Flow stood at $2.9 million, which was up 15141.39% from $12000.0 recorded in Q2 2025.
  • OptimizeRx's 5-year Net Cash Flow high stood at $71.8 million for Q1 2021, and its period low was -$46.1 million during Q3 2022.
  • Its 5-year average for Net Cash Flow is $473784.7, with a median of $115000.0 in 2023.
  • In the last 5 years, OptimizeRx's Net Cash Flow soared by 207006.82% in 2021 and then crashed by 606858.1% in 2022.
  • OptimizeRx's Net Cash Flow (Quarter) stood at -$374808.0 in 2021, then crashed by 6068.58% to -$23.1 million in 2022, then surged by 117.0% to $3.9 million in 2023, then tumbled by 169.87% to -$2.7 million in 2024, then surged by 206.85% to $2.9 million in 2025.
  • Its Net Cash Flow stands at $2.9 million for Q3 2025, versus $12000.0 for Q2 2025 and $3.2 million for Q1 2025.